

Subject: 2022 BPCA Priority List of Needs in Pediatric Therapeutics – Request for Nominations

Good morning,

The *Eunice Kennedy Shriver* National Institute of Child Health and Human Development invites all stakeholders, including physicians, clinicians, researchers, pediatric organizations and associations, patient representatives, and other interested parties, to submit nominations for pediatric research for the Best Pharmaceuticals for Children Act (BPCA) program.

Please submit your nominations at the following link:

<https://www.surveymonkey.com/r/BPCAPrioritization2022>

You may submit the form multiple times if you would like to enter more than one nomination. Nominations will be accepted through **June 1, 2022**.

Nominations for the **BPCA Priority List of Needs in Pediatric Therapeutics** are solicited in order to enhance a program for pediatric drug testing and development as outlined in the BPCA legislation. The Priority List consists of key therapeutic needs in the medical treatment of children and adolescents; it is organized by Therapeutic Area, which can be a group of conditions, a subgroup of the population, or a setting of care.

All nominations received will be considered and evaluated based on set criteria by leading pediatric experts and stakeholder representatives. The final Priority List will be published in the Federal Register and posted on the BPCA website as it sets the agenda for NICHD's focus on future BPCA-related activities.

For further detail, please see the Request for Information (RFI) at [[LINK PENDING](#)].

Please contact [bpca@infinityconferences.com](mailto:bpca@infinityconferences.com) with questions. We look forward to receiving your nomination!

Regards,

Perdita Taylor-Zapata, M.D.

BPCA Program Lead

*Eunice Kennedy Shriver* National Institute of Child Health and Human Development (NICHD)  
National Institutes of Health